SCH-23390 (hydrochloride)

SCH-23390 hydrochloride (R- (+) -SCH-23390 hydrochloride) is a potent and selective dopamine D1-like receptor antagonist with Kis of 0.2 nM and 0.3 nM for the D1 and D5 receptor, respectively. SCH-23390 hydrochloride is a potent and high efficacy human 5-HT2C receptor agonist with a Ki of 9.3 nM. SCH-23390 hydrochloride also binds with high affinity to the 5-HT2 and 5-HT1C receptors. SCH-23390 hydrochloride inhibits G protein-coupled inwardly rectifying potassium (GIRK) channels with an IC50 of 268 nM[1][2][3].

Product Specifications

CAS Number

[125941-87-9]

Product Name Alternative

R- (+) -SCH-23390 hydrochloride

UNSPSC

12352005

Target

5-HT Receptor; Dopamine Receptor; Potassium Channel

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/SCH_23390_hydrochloride.html

Concentration

10mM

Purity

99.83

Solubility

DMSO : ≥ 100 mg/mL|H2O : ≥ 100 mg/mL

Smiles

OC1=C(Cl)C=C2CCN(C)C[C@H](C3=CC=CC=C3)C2=C1.[H]Cl

Molecular Formula

C17H19Cl2NO

Molecular Weight

324.24

References & Citations

[1]Bourne JA, et al . SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev. 2001 Winter;7 (4) :399-414.|[2]Millan MJ, et al. The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology (Berl) . 2001 Jun;156 (1) :58-62.|[3]Kuzhikandathil EV, et al. Classic D1 dopamine receptor antagonist R- (+) -7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) directly inhibits G protein-coupledinwardly rectifying potassium channels. Mol Pharmacol. 2002 Jul;62 (1) :119-26.|[4]Wang YH, et al. Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathway. Acta Pharmacol Sin. 2020 Feb;41 (2) :173-180.|[5]Crockett SL, et al. Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness. Pediatr Res. 2019 Dec 9.